Mind Medicine (MNMD) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 03, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Registrant Name	Mind Medicine (MindMed) Inc.
Entity Central Index Key	0001813814
Trading Symbol	MNMD
Current Fiscal Year End Date	--12-31
Title of 12(b) Security	Common Shares, no par value per share
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity File Number	001-40360
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	98-1582538
Entity Address, Address Line One	One World Trade Center
Entity Address, Address Line Two	Suite 8500
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10007
City Area Code	650
Local Phone Number	208-2454
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Common Stock, Shares Outstanding		427,088,145

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 105,741	$ 133,539
Prepaid and other current assets	3,172	3,676
Right of use asset	177
Total current assets	109,090	137,215
Goodwill	19,918	19,918
Intangible assets, net	5,269	6,869
Total assets	134,277	164,002
Current liabilities:
Accounts payable	732	4,178
Accrued expenses	7,139	6,230
Total current liabilities	7,871	10,408
Other liabilities, long-term	1,902	1,930
Total liabilities	9,773	12,338
Commitments and contingencies (Note 11)
Shareholders' Equity:
Common shares, no par value, unlimited authorized as of June 30, 2022 and December 31, 2021; 426,689,225 and 421,896,217 issued and outstanding as of June 30, 2022 and December 2021, respectively
Additional paid-in capital	296,734	288,290
Accumulated other comprehensive income	850	1,046
Accumulated Deficit	(173,080)	(137,672)
Total shareholders' equity	124,504	151,664
Total liabilities and shareholders' equity	$ 134,277	$ 164,002

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	426,689,225	421,896,217
Common stock, shares outstanding	426,689,225	421,896,217

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 9,326	$ 8,074	$ 19,567	$ 14,887
General and administrative	7,617	37,146	15,881	44,182
Total operating expenses	16,943	45,220	35,448	59,069
Loss from operations	(16,943)	(45,220)	(35,448)	(59,069)
Other income (expense):
Interest income/(expense), net	82	(69)	83	(156)
Foreign exchange gain/(loss), net	(89)	(35)	(44)	134
Other income/(expense)	(7)	72	1	80
Total other income (expense), net	(14)	(32)	40	58
Loss before income taxes	(16,957)	(45,252)	(35,408)	(59,011)
Income taxes	0	0	0	0
Net loss	(16,957)	(45,252)	(35,408)	(59,011)
Other comprehensive gain/(loss):
(Loss)/gain on foreign currency translation	(147)	704	(196)	763
Comprehensive loss	$ (17,104)	$ (44,548)	$ (35,604)	$ (58,248)
Net loss per common share, basic	$ (0.04)	$ (0.11)	$ (0.08)	$ (0.15)
Net loss per common share, diluted	$ (0.04)	$ (0.11)	$ (0.08)	$ (0.15)
Weighted-average common shares, basic	423,630,395	410,823,106	422,951,839	400,322,562
Weighted-average common shares, diluted	423,630,395	410,823,106	422,951,839	400,322,562

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Shares	Additional Paid-In Capital	Accumulated OCI	Accumulated Deficit
Balance at Dec. 31, 2020	$ 75,868		$ 120,220	$ 284	$ (44,636)
Balance, Shares at Dec. 31, 2020		361,135,160
Issuance of Common Shares for vested director compensation	133		133
Issuance of Common Shares for vested director compensation, Shares		1,244,870
Vesting of restricted stock units		1,741,605
Issuance of Common Shares and warrants net of share issuance costs	81,928		81,928
Issuance of Common Shares and warrants net of share issuance costs, Shares		26,930,000
HealthMode acquisition	27,159		27,159
HealthMode acquisition, Shares		8,149,700
Exercise of warrants	10,676		10,676
Exercise of warrants, Shares		7,284,170
Exercise of stock options	5,273		5,273
Exercise of stock options, Shares		10,828,064
Stock-based compensation expense	28,844		28,844
Net loss and Comprehensive loss	(58,248)			763	(59,011)
Balance at Jun. 30, 2021	171,633		274,233	1,047	(103,647)
Balance, Shares at Jun. 30, 2021		417,313,569
Balance at Mar. 31, 2021	180,594		238,646	343	(58,395)
Balance, Shares at Mar. 31, 2021		405,586,054
Issuance of Common Shares for vested director compensation	68		68
Issuance of Common Shares for vested director compensation, Shares		622,435
Vesting of restricted stock units		1,741,605
Issuance of Common Shares and warrants net of share issuance costs	(186)		(186)
Exercise of warrants	3,978		3,978
Exercise of warrants, Shares		3,055,290
Exercise of stock options	4,096		4,096
Exercise of stock options, Shares		6,308,185
Stock-based compensation expense	27,631		27,631
Net loss and Comprehensive loss	(44,548)			704	(45,252)
Balance at Jun. 30, 2021	171,633		274,233	1,047	(103,647)
Balance, Shares at Jun. 30, 2021		417,313,569
Balance at Dec. 31, 2021	151,664		288,290	1,046	(137,672)
Balance, Shares at Dec. 31, 2021		421,896,217
Exercise of warrants	708		708
Exercise of warrants, Shares		1,140,313
Exercise of stock options	$ 164		164
Exercise of stock options, Shares	442,708	442,708
Settlement of restricted share unit awards		3,209,987
Withholding taxes paid on vested restricted share units	$ (407)		(407)
Stock-based compensation expense	7,979		7,979
Net loss and Comprehensive loss	(35,604)			(196)	(35,408)
Balance at Jun. 30, 2022	124,504		296,734	850	(173,080)
Balance, Shares at Jun. 30, 2022		426,689,225
Balance at Mar. 31, 2022	136,805		291,931	997	(156,123)
Balance, Shares at Mar. 31, 2022		422,401,776
Exercise of warrants	590		590
Exercise of warrants, Shares		952,462
Exercise of stock options	41		41
Exercise of stock options, Shares		125,000
Settlement of restricted share unit awards		3,209,987
Stock-based compensation expense	4,172		4,172
Net loss and Comprehensive loss	(17,104)			(147)	(16,957)
Balance at Jun. 30, 2022	$ 124,504		$ 296,734	$ 850	$ (173,080)
Balance, Shares at Jun. 30, 2022		426,689,225

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (35,408)	$ (59,011)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	8,045	34,267
Amortization of intangible assets	1,600	1,039
Non-cash lease expense	17
Changes in operating assets and liabilities:
Prepaid and other current assets	541	56
Accounts payable	(3,429)	(51)
Accrued expenses	792	2,579
Contribution payable	(151)	(88)
Net cash used in operating activities	(27,993)	(21,209)
Cash flows from investing activities
Acquisition, net of cash acquired		(297)
Other investing activities		(86)
Net cash used in financing activities		(383)
Cash flows from financing activities
Proceeds from issuance of share capital, net of issuance costs		81,928
Proceeds from exercise of warrants	708	10,676
Proceeds from exercise of options	123	5,273
Withholding taxes paid on vested restricted stock units	(407)
Net cash provided by financing activities	424	97,877
Effect of exchange rate changes on cash	(229)	719
Net (decrease) increase in cash	(27,798)	77,004
Cash, beginning of period	133,539	80,094
Cash, end of period	105,741	$ 157,098
Supplemental Noncash Disclosures
Right-of-use assets obtained in exchange of operating lease liabilities	$ 194

Nature of Operations

Nature of Operations	6 Months Ended
	Jun. 30, 2022
Nature Of Operations [Abstract]
Description of the Business	1. DESCRIPTION OF THE BUSINESS Mind Medicine (MindMed) Inc. (formerly Broadway Gold Mining Ltd.) (the “Company” or “MindMed”) is incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiaries, Mind Medicine, Inc. (“MindMed US”), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH, are incorporated in Delaware, Delaware, Australia and Switzerland respectively. Prior to February 27, 2020, the Company’s operations were conducted through MindMed US. MindMed US was incorporated on May 30, 2019. On February 27, 2020, MindMed US completed a reverse takeover transaction with Broadway Gold Mining Ltd. (“Broadway”) by way of a plan of arrangement (the "Arrangement") which resulted in Broadway becoming the legal parent company of MindMed US. MindMed US is deemed to be the accounting acquirer in the reverse takeover transaction. The reverse takeover transaction was accounted for as a reverse recapitalization and Broadway was treated as the “acquired” company for accounting purposes. The reverse takeover transaction was accounted as the equivalent of MindMed issuing stock for the net assets of Broadway, accompanied by a recapitalization. Accordingly, all historical financial information for all periods prior to the reverse takeover transaction are the consolidated financial statements of MindMed US, “as if” MindMed US is the predecessor to the Company. As a result, the consolidated balance sheets are presented as a continuance of MindMed US and the comparative figures presented are those of MindMed US. MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The Company's mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. The Company is developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. This specifically includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes including LSD, R(-)-MDMA and zolunicant, or 18-MC, a congener of ibogaine. As of June 30, 2022, the Company had an accumulated deficit of $ 173.1 million. Through June 30, 2022, all the Company’s financial support has primarily been provided by proceeds from the issuance of Common Shares and warrants to purchase Common Shares. As the Company continues its expansion, it may seek additional financing and/or strategic investments however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these financial statements. COVID-19 To the knowledge of the Company’s management as of the date hereof, COVID-19 does not present, at this time, any specific known impacts to the Company in relation to the Company's business objectives or milestones related thereto. The Company relies on third parties to conduct and monitor the Company’s pre-clinical studies and clinical trials. However, to the knowledge of Company’s management, the ability of these third parties to conduct and monitor pre-clinical studies and clinical trials has not been and is not anticipated to be impacted by COVID-19. The Company is not currently aware of any changes in laws, regulations or guidelines, including tax and accounting requirements, arising from COVID-19 which would be reasonably anticipated to materially affect the Company’s business. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the condensed consolidated financial statements may not be comparable to companies that comply with public company FASB standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an EGC.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. BASIS OF pRESENTATION AND Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2021, which are included in the Company’s Annual Report on Form 10-K filed with the SEC. The Company’s significant accounting policies are disclosed in the audited financial statements for the periods ended December 31, 2021 and 2020, included in the Company’s Annual Report on Form 10-K. Since the date of those financial statements, there have been no changes to its significant accounting policies, except as noted below. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates of the Financial Accounting Standards Board (“FASB”). The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates under different assumptions or conditions. Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the condensed consolidated financial statements. Foreign Currency The Company’s reporting currency is the U.S. dollar. The Company's functional currency is the Canadian dollar (“CAD”). The local currency of the Company’s foreign affiliates is generally their functional currency. Accordingly, the assets and liabilities of the foreign affiliates and the parent entity, are translated from their respective functional currency to U.S. dollars using fiscal year-end exchange rates, income and expense accounts are translated at the average rates in effect during the fiscal year and equity accounts are translated at historical rates. Transactions denominated in currencies other than the functional currency are remeasured to the functional currency at the exchange rate on the transaction date. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured at period-end using the period-end exchange rate. Cash and Cash Equivalents The Company considers all investments with an original maturity date at the time of purchase of three months or less to be cash and cash equivalents. Cash equivalents consist primarily of money market funds. The Company’s accounts, at times, may exceed federally insured limits. The Company had no cash equivalents as of March 31, 2022. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption. In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) , which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022 . The Company adopted this standard effective January 1, 2022 , the adoption had no impact on the consolidated financial statements.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	3. ACQUISITIONS HealthMode Acquisition On February 26, 2021 the Company acquired 100 % of the issued and outstanding shares of HealthMode Inc. (“HealthMode”), a developer of technologies using Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring. The Company plans to utilize these technologies in its clinical trials to enhance the quality of the data that is collected during the Company’s clinical trials. The consideration paid for the acquisition of HealthMode was $ 27.6 million, and consisted of $ 0.5 million cash, 81,497 Multiple Voting Shares (equivalent to 8,149,700 Common Shares), valued at approximately $ 27.0 million based upon the closing price of the Company's Common Shares on the acquisition date, and $ 0.1 million in stock options ( 33,619 stock options), which are convertible into Common Shares of the Company. The Company incurred acquisition costs of $ 0.3 million in connection with the acquisition, primarily related to legal, accounting, and other professional services, which were recorded to general and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss for the six months ended June 30, 2021. The Company recognized this transaction as a business combination. The Company recognized approximately $ 9.5 million of identifiable finite-lived intangible assets and $ 19.9 million of goodwill related to the acquisition of HealthMode. The identifiable finite-lived intangible assets are expected to be amortized over their useful lives which are estimated to be three years . The Company has made no adjustments to the purchase price during the measurement period. Actual and pro forma results for this acquisition have not been presented as the financial impact to the Company’s condensed consolidated statement of operations is not material. The goodwill is attributable to the value of the assembled workforce, and the related expertise and developed business function. Further, the acquisition is expected to allow the Company to streamline its product development processes. None of the goodwill is expected to be deductible for tax purposes.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. FAIR VALUE OF FINANCIAL INSTRUMENTS The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2022 and the fair value hierarchy of the valuation techniques utilized. The Company classifies its assets and liabilities as either short- or long-term based on maturity and anticipated realization dates. The Company had no assets measured at fair value on a recurring basis as of December 31, 2021. June 30, 2022 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents $ 80,127 $ — $ — $ 80,127 Financial liabilities: Directors' Deferred Share Unit Liability $ 145 $ — $ — $ 145 December 31, 2021 Level 1 Level 2 Level 3 Total Financial liabilities: Directors' Deferred Share Unit Liability $ 509 $ — $ — $ 509 There were no transfers into or out of Level 1, Level 2, or Level 3 during the six months ended June 3 0 , 2022 and the year ended December 31, 2021.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	5. GOODWILL AND INTANGIBLE ASSETS, NET Goodwill During the six months ended June 30, 2022, the Company has made no additions to its outstanding goodwill. There were no triggering events identified, no indication of impairment of the Company’s goodwill and long-lived assets, and no impairment charges recorded during the three and six months ended June 30, 2022 and 2021. Intangible assets, net The following table summarizes the carrying value of the Company's intangible assets (in thousands): June 30, 2022 Useful Lives Gross Carrying Accumulated Net Carrying Developed Technology 3 $ 9,485 $ ( 4,216 ) $ 5,269 Total intangible assets, net $ 9,485 $ ( 4,216 ) $ 5,269 Developed technology has a remaining useful life of 2.0 years. Amortization expense included in research and development expense was $ 0.8 million and $ 0.8 million for the three months ended June 30, 2022 and 2021, respectively, and $ 1.6 million and $ 1.0 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, the expected future amortization expense for finite-lived intangible assets was as follows (in thousands): Period Ending June 30, Amount 2023 $ 3,162 2024 2,107 Total $ 5,269

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	6. ACCRUED EXPENSES At June 30, 2022 and December 31, 2021, accrued expenses consisted of the following (in thousands): June 30, December 31, 2022 2021 Accrued clinical and manufacturing costs $ 2,184 $ 906 Accrued compensation 2,151 2,295 Professional services 1,604 2,313 Contribution payable 902 713 Lease liabilities 70 — Other payables 228 3 Total accrued expenses $ 7,139 $ 6,230

Shareholders_ Equity

Shareholders’ Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Shareholders’ Equity	7. SHAREHOLDERS’ EQUITY Common Shares The Company is authorized to issue an unlimited number of Common Shares, which have no par value. As of June 30, 2022, the Company had issued and outstanding 426,689,225 shares o f Common Shares. Voting Rights - The holders of Common Shares are entitled to one vote for each Common Share held. All holders of Common Shares are entitled to receive notice of any meeting of shareholders of the Company, and to attend, vote and speak at such meetings, except those meetings at which only holders of a specific class of shares are entitled to vote separately as a class under the Business Corporations Act (British Columbia). A quorum for the transaction of business at any meeting of shareholders is two persons present at the meeting, each of whom is entitled to vote at the meeting, and who hold or represent by proxy in the aggregate not less than 5 % of the outstanding shares of the Company entitled to vote at the meeting. The Company's previous equity structure included Multiple Voting Shares, which had no par value and were eligible to be exchanged with Subordinate Voting Shares on a one-for-one-hundred basis, and Subordinate Voting Shares, which had no par value and were equivalent in rights to Common Shares . All share data shown in the accompanying condensed consolidated financial statements and related notes has been retroactively revised to reflect the conversion of all outstanding Multiple Voting Shares and Subordinate Voting Shares to Common Shares as of June 30, 2022. During the first quarter of 2022, holders of 4,521 Multiple Voting Shares exchanged their shares for 452,060 Subordinate Voting Shares on a one-for-one-hundred basis. These Subordinate Voting Shares were subsequently redesignated as Common Shares as of June 30, 2022. Shelf Registration and At-The-Market Facility On May 4, 2022, the Company filed a shelf registration statement on Form S-3 (the “Registration Statement”). Pursuant to the Registration Statement, the Company may offer and sell securities having an aggregate public offering price of up to $ 200.0 million. In connection with the filing of the Registration Statement, the Company also entered into a sales agreement with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. as sales agents (together, the “Sales Agents”), pursuant to which the Company may issue and sell Common Shares for an aggregate offering price of up to $ 100.0 million under an at-the-market offering program (the “ATM”). Pursuant to the ATM, the Company will pay the Sales Agents a commission rate equal to 3.0 % of the gross proceeds from the sale of any Common Shares. The Company is not obligated to make any sales of its Common Shares under the ATM. The Company has no t sold any of its Common Shares under the ATM as of June 30, 2022.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	8. WARRANTS Bought Deal Compensation and Financing Warrants The below table represents the activity associated with the Company's outstanding equity classified Compensation and Financing warrants for the six months ended June 30, 2022: Compensation Warrants Financing Weighted Balance – December 31, 2021 1,888,350 20,651,580 4.24 Issued — — — Exercised — ( 1,140,313 ) 0.79 Expired — ( 217,042 ) 0.79 Balance – June 30, 2022 1,888,350 19,294,225 4.49 The weighted average market fair value of shares purchased through warrant exercises during the six months ended June 30, 2022 was CAD$ 1.10 .

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	9. STOCK-BASED COMPENSATION Stock Incentive Plan 2020 Plan On February 27, 2020, the Company adopted the MindMed Stock Option Plan (the “Plan”) to advance the interests of the Company by providing employees, contractors and directors of the Company a performance incentive for continued and improved service with the Company. The Plan sets out the framework for determining eligibility as well as the terms of any stock-based compensation granted. The plan was approved by the shareholders as part of the Arrangement and is authorized to issue 15 % of the Company's outstanding Common Shares under the terms of the plan. The fair value of options issued is estimated using the Black-Scholes-Merton option pricing model on the date of grant with the following assumptions: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Share price $ 1.00 CAD - 1.19 $ 2.73 CAD - 4.46 $ 1.00 CAD - 1.78 $ 2.73 CAD - 4.46 Expected volatility 92.73 % - 97.92 % 71.62 % - 102.89 % 92.73 % - 97.92 % 71.62 % - 102.89 % Risk-free rate 2.71 % - 2.78 % 0.02 % - 0.50 % 1.79 % - 2.78 % 0.02 % - 0.50 % Expected life 2.5 - 3.6 years 0.3 - 3.6 years 2.5 - 3.6 years 0.3 - 3.6 years Expected dividend yield 0 % 0 % 0 % 0 % The following table summarizes the Company’s stock option activity: Number of Options Weighted Average Exercise Price (CAD$) Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options outstanding – December 31, 2021 23,093,044 $ 1.86 3.8 $ 13,610,348 Issued 10,382,116 1.43 Exercised ( 442,708 ) 0.45 488,177 Forfeited ( 666,228 ) 2.49 Expired ( 713,669 ) 3.00 Options outstanding – June 30, 2022 31,652,555 $ 1.70 3.9 $ 3,755,347 Options vested and exercisable at June 30, 2022 7,951,967 $ 1.57 3.8 $ 2,093,667 The weighted average grant date fair value of options granted during the six months ended June 30, 2022 was CAD$ 0.96 . The aggregated fair value of options vested during the six months ended June 30, 2022 was $ 5.7 million. The expense recognized related to options during the three and six months ended June 30, 2022 w as $ 1.9 million and $ 4.0 m illion, respectively. Restricted Share Units The Company has adopted a Performance and Restricted Share Unit (“RSU”) Plan to advance the interests of the Company by providing employees, contractors and directors of the Company a performance incentive for continued and improved service with the Company. The plan sets out the framework for determining eligibility as well as the terms of any stock-based compensation granted. The plan was approved by the shareholders as part of the Arrangement. The fair value has been estimated based on the closing price of the stock on the day prior to the grant. Number of RSUs Weighted Average Grant Date Fair Value (CAD$) Balance December 31, 2021 9,667,217 $ 3.00 Granted 7,812,180 1.44 Vested and unissued ( 3,175,731 ) 2.54 Cancelled ( 334,599 ) 3.56 Balance June 30, 2022 13,969,067 $ 2.22 The fair market value of RSUs vested during the six months ended June 30, 2022 was $ 4.0 million. The expense recognized related to RSUs during the three and six months ended June 30, 2022 w as $ 2.3 million and $ 3.9 m illion, respectively. Directors' Deferred Share Unit Plan 2021 Plan On April 16, 2021, the Company adopted the MindMed Director's Deferred Share Unit Plan (the "DDSU Plan"). The DDSU Plan sets out a framework to grant non-executive directors DDSU's which are cash settled awards. The DDSU Plan states that the fair market value of one DDSU shall be equal to the volume weighted average trading price of a Common Share on the NEO Exchange for the five business days immediately preceding the date upon which any payment is made to settle the DDSUs. The DDSU's generally vest ratably over twelve months after grant and are settled within 90 days of the date the director ceases service to the Company. Number of DDSUs Balance December 31, 2021 456,260 Issued 2,113,667 Settled — Cancelled ( 370,491 ) Balance June 30, 2022 2,199,436 For the six months ended June 30, 2022, $ 0.1 million of stock-based compensation expense was recognized relating to the revaluation of the vested DDSUs, recorded in general and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss. There were 596,550 DDSUs vested as of June 30, 2022. The liability associated with the outstanding vested DDSUs was $ 0.1 million as of June 30, 2022 and was recorded to accrued expenses in the accompanying condensed consolidated balance sheet. Stock-based Compensation Expense Stock-based compensation expense for all equity arrangements for the three and six months ended June 30, 2022 and 2021 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 1,779 $ 2,427 $ 3,784 $ 2,768 General and administrative 2,474 30,561 4,261 31,499 Total stock-based compensation expense $ 4,253 $ 32,988 $ 8,045 $ 34,267 As of June 30, 2022, there was approximately $ 19.9 million of total unrecognized stock-based compensation expense, related to unvested options granted to employees under the Company’s stock option plan that is expected to be recognized over a weighted average period of 3 years. As of June 30, 2022, there was approximately $ 21.7 million of total unrecognized stock-based compensation expense, related to RSUs granted to employees under the Company’s stock option plan that is expected to be recognized over a weighted average period of 3.1 years.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES The Company’s effective tax rat e was 0 % for the t hree and six months ended June 30, 2022 and 2021. The Company’s effective rate is primarily driven by its jurisdictional earnings by location and a valuation allowance that eliminates the Company’s global net deferred tax assets. The Company assesses the realizability of its deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. COMMITMENTS AND CONTINGENCIES As of June 30, 2022, the Company has obligations to make future payments, representing significant research and development contracts and other commitments that are known and committed in the amount of approximat ely $ 33.7 million . Most of these agreements are cancelable by the Company with notice. These commitments include agreements related to the conduct of the clinical trials, sponsored research, manufacturing, and preclinical studies. The Company enters into research, development, and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which are uncertain. The Company periodically enters into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the condensed consolidated financial statements with respect to these indemnification obligations. Operating Lease Agreement During April 2022, the Company entered into a 3 -year operating lease for office space located in North Carolina. Total lease payments under the lease amount to approximately $ 0.2 million and the Company recorded a related right-of-use asset and related lease liability upon lease commencement of approximately $ 0.2 million. The current portion of the lease liability is recorded in accrued expenses and the noncurrent portion is recorded in other liabilities, long-term in the accompanying condensed consolidated balance sheet.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	12. RELATED PARTY TRANSACTIONS The Company had no related party expenses during the three and six months ended June 30, 2022. The Company incurred nominal legal fees and $ 0.4 million to companies controlled by a former director of the Company during the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, the Company had a nominal amount of accounts payable and accrued liabilities outstanding due to a company controlled by a former director.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2021, which are included in the Company’s Annual Report on Form 10-K filed with the SEC. The Company’s significant accounting policies are disclosed in the audited financial statements for the periods ended December 31, 2021 and 2020, included in the Company’s Annual Report on Form 10-K. Since the date of those financial statements, there have been no changes to its significant accounting policies, except as noted below. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates of the Financial Accounting Standards Board (“FASB”). The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates under different assumptions or conditions. Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the condensed consolidated financial statements.
Foreign Currency	Foreign Currency The Company’s reporting currency is the U.S. dollar. The Company's functional currency is the Canadian dollar (“CAD”). The local currency of the Company’s foreign affiliates is generally their functional currency. Accordingly, the assets and liabilities of the foreign affiliates and the parent entity, are translated from their respective functional currency to U.S. dollars using fiscal year-end exchange rates, income and expense accounts are translated at the average rates in effect during the fiscal year and equity accounts are translated at historical rates. Transactions denominated in currencies other than the functional currency are remeasured to the functional currency at the exchange rate on the transaction date. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured at period-end using the period-end exchange rate.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all investments with an original maturity date at the time of purchase of three months or less to be cash and cash equivalents. Cash equivalents consist primarily of money market funds. The Company’s accounts, at times, may exceed federally insured limits. The Company had no cash equivalents as of March 31, 2022.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption. In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) , which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On April 8, 2020, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022 . The Company adopted this standard effective January 1, 2022 , the adoption had no impact on the consolidated financial statements.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2022 and the fair value hierarchy of the valuation techniques utilized. June 30, 2022 Level 1 Level 2 Level 3 Total Financial assets: Cash equivalents $ 80,127 $ — $ — $ 80,127 Financial liabilities: Directors' Deferred Share Unit Liability $ 145 $ — $ — $ 145 December 31, 2021 Level 1 Level 2 Level 3 Total Financial liabilities: Directors' Deferred Share Unit Liability $ 509 $ — $ — $ 509

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Value of Intangible Assets	The following table summarizes the carrying value of the Company's intangible assets (in thousands): June 30, 2022 Useful Lives Gross Carrying Accumulated Net Carrying Developed Technology 3 $ 9,485 $ ( 4,216 ) $ 5,269 Total intangible assets, net $ 9,485 $ ( 4,216 ) $ 5,269
Summary of Expected Future Amortization Expense for Finite-lived Intangible Assets	As of June 30, 2022, the expected future amortization expense for finite-lived intangible assets was as follows (in thousands): Period Ending June 30, Amount 2023 $ 3,162 2024 2,107 Total $ 5,269

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Summary of Accrued Expenses	At June 30, 2022 and December 31, 2021, accrued expenses consisted of the following (in thousands): June 30, December 31, 2022 2021 Accrued clinical and manufacturing costs $ 2,184 $ 906 Accrued compensation 2,151 2,295 Professional services 1,604 2,313 Contribution payable 902 713 Lease liabilities 70 — Other payables 228 3 Total accrued expenses $ 7,139 $ 6,230

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrants and Weighted Average Exercise Price	The below table represents the activity associated with the Company's outstanding equity classified Compensation and Financing warrants for the six months ended June 30, 2022: Compensation Warrants Financing Weighted Balance – December 31, 2021 1,888,350 20,651,580 4.24 Issued — — — Exercised — ( 1,140,313 ) 0.79 Expired — ( 217,042 ) 0.79 Balance – June 30, 2022 1,888,350 19,294,225 4.49

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Fair Value Assumptions of Options	The fair value of options issued is estimated using the Black-Scholes-Merton option pricing model on the date of grant with the following assumptions: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Share price $ 1.00 CAD - 1.19 $ 2.73 CAD - 4.46 $ 1.00 CAD - 1.78 $ 2.73 CAD - 4.46 Expected volatility 92.73 % - 97.92 % 71.62 % - 102.89 % 92.73 % - 97.92 % 71.62 % - 102.89 % Risk-free rate 2.71 % - 2.78 % 0.02 % - 0.50 % 1.79 % - 2.78 % 0.02 % - 0.50 % Expected life 2.5 - 3.6 years 0.3 - 3.6 years 2.5 - 3.6 years 0.3 - 3.6 years Expected dividend yield 0 % 0 % 0 % 0 %
Schedule of Stock Option Activity	The following table summarizes the Company’s stock option activity: Number of Options Weighted Average Exercise Price (CAD$) Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options outstanding – December 31, 2021 23,093,044 $ 1.86 3.8 $ 13,610,348 Issued 10,382,116 1.43 Exercised ( 442,708 ) 0.45 488,177 Forfeited ( 666,228 ) 2.49 Expired ( 713,669 ) 3.00 Options outstanding – June 30, 2022 31,652,555 $ 1.70 3.9 $ 3,755,347 Options vested and exercisable at June 30, 2022 7,951,967 $ 1.57 3.8 $ 2,093,667
Schedule of Restricted Share Units	The Company has adopted a Performance and Restricted Share Unit (“RSU”) Plan to advance the interests of the Company by providing employees, contractors and directors of the Company a performance incentive for continued and improved service with the Company. The plan sets out the framework for determining eligibility as well as the terms of any stock-based compensation granted. The plan was approved by the shareholders as part of the Arrangement. The fair value has been estimated based on the closing price of the stock on the day prior to the grant. Number of RSUs Weighted Average Grant Date Fair Value (CAD$) Balance December 31, 2021 9,667,217 $ 3.00 Granted 7,812,180 1.44 Vested and unissued ( 3,175,731 ) 2.54 Cancelled ( 334,599 ) 3.56 Balance June 30, 2022 13,969,067 $ 2.22
Schedule of Directors' Deferred Share Unit Plan	On April 16, 2021, the Company adopted the MindMed Director's Deferred Share Unit Plan (the "DDSU Plan"). The DDSU Plan sets out a framework to grant non-executive directors DDSU's which are cash settled awards. The DDSU Plan states that the fair market value of one DDSU shall be equal to the volume weighted average trading price of a Common Share on the NEO Exchange for the five business days immediately preceding the date upon which any payment is made to settle the DDSUs. The DDSU's generally vest ratably over twelve months after grant and are settled within 90 days of the date the director ceases service to the Company. Number of DDSUs Balance December 31, 2021 456,260 Issued 2,113,667 Settled — Cancelled ( 370,491 ) Balance June 30, 2022 2,199,436
Summary of Stock-based Compensation Expense	Stock-based compensation expense for all equity arrangements for the three and six months ended June 30, 2022 and 2021 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 1,779 $ 2,427 $ 3,784 $ 2,768 General and administrative 2,474 30,561 4,261 31,499 Total stock-based compensation expense $ 4,253 $ 32,988 $ 8,045 $ 34,267

Description of the Business - A

Description of the Business - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Deficit	$ (173,080)	$ (137,672)

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash equivalents		$ 0
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($)	Feb. 26, 2021	Jun. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill		$ 19,918,000	$ 19,918,000
HealthMode Acquisition
Business Acquisition [Line Items]
Business acquisition date	Feb. 26, 2021
Acquired percentage of issued and outstanding shares	100%
Consideration paid for acquisition	$ 27,600,000
Cash paid for acquisition	500,000
Multiple voting share paid for acquisition	27,000,000
Stock options paid for acquisition	$ 100,000
Number of stock options issued	33,619
Recognized identifiable finite-live intangible assets	$ 9,500,000
Goodwill	$ 19,900,000
Intangible assets, useful life	3 years
Business acquisition, goodwill expected tax deductible amount	$ 0
Business combination, acquisition costs	300,000
Adjustment to purchase price during measurement period	$ 0
HealthMode Acquisition | Common Shares
Business Acquisition [Line Items]
Voting shares issued	8,149,700
HealthMode Acquisition | Multiple Voting Shares
Business Acquisition [Line Items]
Voting shares issued	81,497

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Financial Assets, Fair Value Disclosure [Abstract]
Cash equivalents	$ 80,127
Directors' Deferred Share Unit Liability
Financial Liabilities Fair Value Disclosure [Abstract]
Financial liabilities	145	$ 509
Level 1
Financial Assets, Fair Value Disclosure [Abstract]
Cash equivalents	80,127
Level 1 | Directors' Deferred Share Unit Liability
Financial Liabilities Fair Value Disclosure [Abstract]
Financial liabilities	$ 145	$ 509

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Assets measured at fair value on recurring basis		$ 0
Fair value of assets transfers into Level 3	$ 0	0
Fair value of assets transfers out of Level 3	0	0
Fair value of liabilities transfers into Level 3	0	0
Fair value of liabilities transfers out of Level 3	$ 0	$ 0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Goodwill acquired during period			$ 0
Impairment charges of goodwill	$ 0	$ 0	0	$ 0
Amortization of Intangible Assets	800,000	800,000	1,600,000	1,039,000
Indication of impairment of goodwill and long-lived assets	$ 0	$ 0	$ 0	$ 0
Development Technology
Finite-Lived Intangible Assets [Line Items]
Intangible assets remaining useful life			2 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Summary of Carrying Value of Intangible Assets (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Value	$ 9,485
Intangible assets, Accumulated Amortization	(4,216)
Intangible assets, Net Carrying Value	$ 5,269
Development Technology
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful Lives (in years)	3 years
Intangible assets, Gross Carrying Value	$ 9,485
Intangible assets, Accumulated Amortization	(4,216)
Intangible assets, Net Carrying Value	$ 5,269

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Summary of Expected Future Amortization Expense for finite-lived intangible assets (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 3,162
2024	2,107
Intangible assets, Net Carrying Value	$ 5,269

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued clinical and manufacturing costs	$ 2,184	$ 906
Accrued compensation	2,151	2,295
Professional services	1,604	2,313
Contribution payable	902	713
Lease liabilities	70
Other payables	228	3
Total accrued expenses	$ 7,139	$ 6,230

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details)		3 Months Ended	6 Months Ended
	May 04, 2022 USD ($)	Mar. 31, 2022 shares	Jun. 30, 2022 Vote $ / shares shares	Dec. 31, 2021 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, no par value | $ / shares			$ 0
Number of shares issued and outstanding			426,689,225
Common stock, number of votes per share held | Vote			1
Common stock conversion basis			The Company's previous equity structure included Multiple Voting Shares, which had no par value and were eligible to be exchanged with Subordinate Voting Shares on a one-for-one-hundred basis, and Subordinate Voting Shares, which had no par value and were equivalent in rights to Common Shares. All share data shown in the accompanying condensed consolidated financial statements and related notes has been retroactively revised to reflect the conversion of all outstanding Multiple Voting Shares and Subordinate Voting Shares to Common Shares as of June 30, 2022.
Common stock, shares issued			426,689,225	421,896,217
At-the-market Offering Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued			0
Percentage of gross proceeds from sales of common shares payable as sales agent commission rate	3%
Minimum | Common Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of outstanding shares to be held to vote			5%
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of securities aggregate public offering price | $	$ 200,000,000
Maximum | At-the-market Offering Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Sale of securities aggregate public offering price | $	$ 100,000,000
Subordinate Voting Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, no par value | $ / shares			$ 0
Conversion of convertible shares		452,060
Multiple Voting Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, no par value | $ / shares			$ 0
Common stock, shares issued		4,521

Warrants - Additional Informati

Warrants - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares
Warrants and Rights Note Disclosure [Abstract]
Weighted average fair value of shares purchased upon exercise of warrants	$ 1.10

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants and Weighted Average Exercise Price (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Compensation Warrants
Class Of Warrant Or Right [Line Items]
Beginning balance, shares	1,888,350
Issued, shares	0
Exercised, shares	0
Expired, shares	0
Ending balance, shares	1,888,350
Financing Warrants
Class Of Warrant Or Right [Line Items]
Beginning balance, shares	20,651,580
Issued, shares	0
Exercised, shares	(1,140,313)
Expired, shares	(217,042)
Ending balance, shares	19,294,225
Compensation and Financing Warrants
Class Of Warrant Or Right [Line Items]
Beginning balance, weighted average exercise price | $ / shares	$ 4.24
Issued, weighted average exercise price | $ / shares	0
Exercised, weighted average exercise price | $ / shares	0.79
Expired, weighted average exercise price | $ / shares	0.79
Ending balance, weighted average exercise price | $ / shares	$ 4.49

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) $ in Thousands		3 Months Ended		6 Months Ended
	Feb. 27, 2020	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value of options granted | $ / shares					$ 0.96
Aggregated fair value of options vested				$ 5,700
Number of shares, vested | shares				596,550
Stock-based compensation expense recognized		$ 4,253	$ 32,988	$ 8,045		$ 34,267
Accrued expenses		7,139		7,139	$ 7,139		$ 6,230
Unrecognized stock-based compensation expense related to unvested options granted		19,900		$ 19,900	19,900
Weighted average period for recognition of unvested options granted				3 years
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized		2,474	$ 30,561	$ 4,261		$ 31,499
Restricted Share Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized		2,300		3,900
Fair market value of vested shares				4,000
Unrecognized stock-based compensation expense related to unvested options granted		21,700		$ 21,700	21,700
Weighted average period for recognition of unvested options granted				3 years 1 month 6 days
Directors' Deferred Share Unit Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Accrued expenses		100		$ 100	$ 100
Directors' Deferred Share Unit Plan | General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized				100
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized		$ 1,900		$ 4,000
MindMed Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage	15%
Vesting rights, description				The plan was approved by the shareholders as part of the Arrangement and is authorized to issue 15% of the Company's outstanding Common Shares under the terms of the plan.

Stock-based compensation - Sche

Stock-based compensation - Schedule of Fair Value Assumptions of Options (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, minimum	92.73%	71.62%	92.73%	71.62%
Expected volatility, maximum	97.92%	102.89%	97.92%	102.89%
Risk-free rate, minimum	2.71%	0.02%	1.79%	0.02%
Risk-free rate, maximum	2.78%	0.50%	2.78%	0.50%
Expected dividend yield	0%	0%	0%	0%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price	$ 1	$ 2.73	$ 1	$ 2.73
Expected life	2 months 15 days	3 months 18 days	2 years 6 months	3 months 18 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price	$ 1.19	$ 4.46	$ 1.78	$ 4.46
Expected life	3 years 7 months 6 days	3 years 7 months 6 days	3 years 7 months 6 days	3 years 7 months 6 days

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 CAD ($) $ / shares shares	Dec. 31, 2021 CAD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of options, outstanding | shares	23,093,044
Number of options, issued | shares	10,382,116
Number of options, exercised | shares	(442,708)
Number of options, forfeited | shares	(666,228)
Number of options, expired | shares	(713,669)
Number of options, outstanding | shares	31,652,555	23,093,044
Number of options, vested and exercisable | shares	7,951,967
Weighted average exercise price, outstanding | $ / shares	$ 1.86
Weighted average exercise price, issued | $ / shares	1.43
Weighted average exercise price, exercised | $ / shares	0.45
Weighted average exercise price, forfeited | $ / shares	2.49
Weighted average exercise price, expired | $ / shares	3
Weighted average exercise price, outstanding | $ / shares	1.70	$ 1.86
Weighted average exercise price, vested and exercisable | $ / shares	$ 1.57
Weighted average remaining contractual life (Years), outstanding	3 years 10 months 24 days	3 years 9 months 18 days
Weighted average remaining contractual life (Years), vested and exercisable	3 years 9 months 18 days
Aggregate intrinsic value, outstanding | $	$ 13,610,348
Aggregate intrinsic value, exercised | $	488,177
Aggregate intrinsic value, outstanding | $	3,755,347	$ 13,610,348
Aggregate intrinsic value, vested and exercisable | $	$ 2,093,667

Stock-based Compensation - Sc_3

Stock-based Compensation - Schedule of Restricted Share Units (Details) - Restricted Share Units	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, beginning balance | shares	9,667,217
Number of shares, granted | shares	7,812,180
Number of shares, vested and unissued | shares	3,175,731
Number of shares, cancelled | shares	(334,599)
Number of shares, ending balance | shares	13,969,067
Weighted average grant date fair value, beginning balance | $ / shares	$ 3
Weighted average grant date fair value, granted | $ / shares	1.44
Weighted average grant date fair value, vested and unissued | $ / shares	2.54
Weighted average grant date fair value, cancelled | $ / shares	3.56
Weighted average grant date fair value, ending balance | $ / shares	$ 2.22

Stock-based Compensation - Sc_4

Stock-based Compensation - Schedule of Directors' Deferred Share Unit Plan (Details) - Directors' Deferred Share Unit Plan	6 Months Ended
	Jun. 30, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, beginning balance	456,260
Number of shares, granted	2,113,667
Number of shares, settled	0
Number of shares, cancelled	(370,491)
Number of shares, ending balance	2,199,436

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,253	$ 32,988	$ 8,045	$ 34,267
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,779	2,427	3,784	2,768
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,474	$ 30,561	$ 4,261	$ 31,499

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Tax rate	0%	0%	0%	0%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2022	Jun. 30, 2022
Other commitment		$ 33.7
Lease payment	$ 0.2
Right-of-use asset	0.2
Lease liability	$ 0.2
NC
Operating lease term	3 years

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transactions [Abstract]
Related party expenses	$ 0		$ 0
Nominal legal fees		$ 400,000		$ 400,000